Chike Okechukwu, MD
Nephrology · Upland, PANPI 1174578215
Payments from drug & device makers
Across 157 payments — averaging $5575.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$269K
- GSK$235K
- AstraZeneca$187K
- Eli Lilly$142K
- CSL Behring$19K
- Merck$11K
- plus $12K from 21 others
Across 3 payments — averaging $5152.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$15K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 8 | $269,130 |
| GSK | 7 | $234,833 |
| AstraZeneca(2 entities) | 27 | $186,611 |
| Eli Lilly | 28 | $142,242 |
| CSL Behring | 8 | $19,065 |
| Merck | 10 | $11,149 |
| Travere Therapeutics, Inc. | 7 | $8,376 |
| Otsuka America Pharmaceutical, Inc. | 7 | $2,299 |
| Vifor Pharma, Inc. | 13 | $307 |
| Bayer | 8 | $166 |
| Novo Nordisk | 2 | $150 |
| Calliditas Therapeutics US Inc. | 3 | $148 |
| Amgen | 6 | $132 |
| Akebia Therapeutics Inc | 1 | $125 |
| Aurinia Pharma U.S., Inc. | 2 | $123 |
| Mallinckrodt Enterprises LLC | 2 | $121 |
| Novartis | 5 | $92 |
| Ardelyx, Inc. | 2 | $50 |
| Fresenius USA Marketing, Inc. | 2 | $37 |
| Scpharmaceuticals Inc. | 1 | $30 |
| Boehringer Ingelheim | 2 | $28 |
| Lilly USA, LLC | 1 | $28 |
| Johnson & Johnson | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Sanofi | 1 | $19 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $11 |
How this compares
$875,333 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Upland
- Roy MarcusUpland$425K
- Katalin SusztakPhiladelphia$4.8M
- Debbie Cohen SteinPhiladelphia$2.8M
- Nelson KopytAllentown$2.1M
- Iris LeePhiladelphia$1.9M
- Abdallahsassine GearaPhiladelphia$1.2M
- Alexander ChangDanville$1000K
- Gaia MuallemPhiladelphia$942K
- Christopher GislerPittsburgh$757K
- Umar FarooqHershey$723K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.